Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Venous Thromboembolism 12Venous Thrombosis 9Pulmonary Embolism 9Neoplasms 8Thrombosis 4Pancreatic Neoplasms 3Multiple Myeloma 3Lung Neoplasms 3Thromboembolism 2Neoplasm Metastasis 2Lymphoma 2Hemorrhage 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Thrombophilia 1Thrombocytopenia 1Thrombocythemia, Essential 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Ovarian Neoplasms 1Obesity 1Neoplasms, Plasma Cell 1Myeloproliferative Disorders 1

Interventions

Warfarin 1Dalteparin 14-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Embolism and Thrombosis × Dalteparin × Clear all
NCT00216866 2017-08-28

The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Phase 2 Completed
70 enrolled

Embolism, Thrombosis, Embolism and Thrombosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡